Logo image
Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series
Journal article   Open access   Peer reviewed

Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series

Masaaki Yamada, Eiyu Matsumoto, Christie P Thomas, Jennifer R Carlson, Stacey J Klutts, Bharat Kumar, Judy A Streit and Melissa L Swee
Transplantation direct, Vol.7(9), pp.e743-e743
09/01/2021
DOI: 10.1097/TXD.0000000000001193
PMCID: PMC8352604
PMID: 34386580
url
https://doi.org/10.1097/TXD.0000000000001193View
Published (Version of record) Open Access

Abstract

The ongoing global pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the rapid development of several safe and effective vaccines.1 The earliest to receive emergency use authorization by the US Food and Drug Administration were 2 novel mRNA vaccines. The short-term efficacy of these mRNA vaccines from their phase 3 trials has been comparable with that of highly effective conventional vaccines. In healthy trial participants, these mRNA vaccines reduced symptomatic SARS-CoV-2 infection by over 90%.2-4 However, the efficacy and long-term immunogenicity of SARS-CoV-2 mRNA vaccines have not yet been thoroughly studied in immunocompromised populations. One of the earliest studies reported reduced humoral response to mRNA vaccine in solid organ transplant (SOT) recipients.5 We report a case of a long-term kidney transplant recipient on stable maintenance immunosuppression who acquired COVID-19 with onset of symptoms about 11 d after his second dose of SARS-CoV-2 mRNA vaccine.

Details

Metrics

Logo image